WO2007122721A1 - Fiber and fiber products for relieving symptoms of fibromuscular pain - Google Patents

Fiber and fiber products for relieving symptoms of fibromuscular pain Download PDF

Info

Publication number
WO2007122721A1
WO2007122721A1 PCT/JP2006/308392 JP2006308392W WO2007122721A1 WO 2007122721 A1 WO2007122721 A1 WO 2007122721A1 JP 2006308392 W JP2006308392 W JP 2006308392W WO 2007122721 A1 WO2007122721 A1 WO 2007122721A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon fiber
fiber
fibromyalgia
present
symptom
Prior art date
Application number
PCT/JP2006/308392
Other languages
French (fr)
Japanese (ja)
Inventor
Yasuhiko Munakata
Original Assignee
Therath Medico, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therath Medico, Inc. filed Critical Therath Medico, Inc.
Priority to JP2006525407A priority Critical patent/JPWO2007122721A1/en
Priority to PCT/JP2006/308392 priority patent/WO2007122721A1/en
Publication of WO2007122721A1 publication Critical patent/WO2007122721A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C27/00Spring, stuffed or fluid mattresses or cushions specially adapted for chairs, beds or sofas
    • A47C27/12Spring, stuffed or fluid mattresses or cushions specially adapted for chairs, beds or sofas with fibrous inlays, e.g. made of wool, of cotton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • D01F9/08Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
    • D01F9/12Carbon filaments; Apparatus specially adapted for the manufacture thereof
    • D01F9/14Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments
    • D01F9/16Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments from products of vegetable origin or derivatives thereof, e.g. from cellulose acetate
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M13/00Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
    • AHUMAN NECESSITIES
    • A41WEARING APPAREL
    • A41BSHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
    • A41B2400/00Functions or special features of shirts, underwear, baby linen or handkerchiefs not provided for in other groups of this subclass
    • A41B2400/32Therapeutic use
    • AHUMAN NECESSITIES
    • A41WEARING APPAREL
    • A41DOUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
    • A41D2400/00Functions or special features of garments
    • A41D2400/32Therapeutic use
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M2101/00Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
    • D06M2101/40Fibres of carbon

Definitions

  • the present invention relates to a fibromyalgia symptom-relieving fiber, a textile product, a mat, clothing, and a vest.
  • Patent Document 1 Japanese Patent Laid-Open No. 2000-160476
  • Patent Document 2 Utility Model Registration No. 3098293
  • Patent Document 3 Utility Model Registration No. 3095112
  • Patent Document 4 Japanese Unexamined Patent Application Publication No. 2004-223188
  • Non-Patent Document 1 The 81st Annual Meeting of the Kanto Branch of the Bacteriological Society of Japan
  • Non-Patent Document 2 10th Annual Meeting of the Japanese Endovascular Society Program
  • Fibromyalgia has become a problem as an unknown disease. Fibromyalgia is a disease that causes pain, numbness, etc. throughout the body or area of the body, and is accompanied by insomnia, headache, slight fever, and fatigue.
  • Table 1 shows the symptoms of fibromyalgia. [Table 1] Fibromyalgia symptoms
  • treatment methods include blocking cervical stellate ganglia by injection or low-power laser, and taking drugs such as anti-anxiety drugs, antidepressants, and antiepileptic drugs.
  • the present invention has been made paying attention to such a problem, and can be treated regardless of location, and can easily relieve the symptoms of fibromyalgia without side effects.
  • Symptoms of Means for solving the problems aimed at providing fibers, textiles, mats, clothing and vests
  • the fibromyalgia symptom alleviating fiber according to the present invention is composed of carbon fiber made of cotton.
  • the fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet shape.
  • a method for forming a sheet for example, a knitting method, a non-woven fabric or other method of sandwiching between two cloths, and a method of enclosing in a cloth bag are preferable.
  • processing into a sheet it is preferable to process to a density of 1200 to 1300 gZm 2 and a thickness of about 2 to 3 mm.
  • the fibromyalgia symptom alleviating fiber according to the present invention has an effect of relieving fibromyalgia symptom by being placed as close as possible to the positions of 18 "tenderness points" on the body. is there.
  • the degree of closeness may be as small as one or two underwear or sheets that do not need to be touched directly on the skin, or just touch the “tenderness point” through the fabric.
  • Tender point exists symmetrically on both sides of the body, and when palpated at a strength of about 4kg, “not painful”, “slightly painful”, “moderately painful” and “very painful” In the four stages of "", it is the part that feels more than "a little painful”.
  • the occipital region, lower cervical vertebrae, trapezius, supraspinatus, second gastrocnemius, lateral epicondyle, buttocks, greater trochanter and knee are the characteristic “tender point” positions in fibromyalgia.
  • the occipital region with the suboccipital tendon
  • the lower cervical vertebra anterior between the 5th and 7th cervical vertebrae
  • the trapezius the middle of the upper edge
  • Supraspinous muscle origin, above the scapula spine near the inner edge
  • second gluteal muscle second rib-one costal cartilage joint, just outside the joint
  • lateral epicondyle upper 2cm distal from the Yori
  • buttocks 4 semi-upper outer side of the buttocks
  • greater trochanter posterior part of the trochanter
  • knee a pair of fluffy parts on the inside and slightly above The place is the tender point.
  • Figure 1 shows the location of the tender point.
  • fibromyalgia symptom alleviating fiber it is preferable to maintain and apply the condition simultaneously applied to all of the 18 “tenderness points” in order to enhance and sustain the symptom relief effect. . Furthermore, it is preferable to cover the whole body. However, the effect of relieving the symptoms of fibromyalgia is also observed when used on only one of the “tenderness points”. "Tender point” It may be applied to other painful places. In addition, it does not always need to be applied, and it can be used only during the daytime or only during the nighttime.
  • the fibromyalgia symptom alleviating fiber according to the present invention can be treated at any place, and can easily relieve the fibromyalgia symptom without side effects.
  • the mechanism of action of the fibromyalgia symptom relief fiber according to the present invention is unknown.
  • Carbon fiber is known to have a far-infrared radiation effect, but far-infrared radiation alone has little effect on the symptoms of fibromyalgia. It is considered a synergistic effect.
  • the fibromyalgia symptom-relieving fiber according to the present invention is obtained by impregnating and drying a treatment liquid mainly composed of wood vinegar, bamboo vinegar, or both into cotton fibers. It is preferable. In this case, bactericidal and antibacterial properties can be obtained.
  • the processing solution may contain mugwort extract.
  • immersion is preferred. In this case, it is preferable to wash the carbon fiber soaked with distilled water and then dry it.
  • the drying method vacuum drying or hot air drying is preferred.
  • the fibromyalgia symptom alleviating fiber according to the present invention is limited to carbon fiber made from cotton.
  • Carbon fibers made from cotton are preferably carbonized carbonized at a high temperature of 800 ° C or higher, preferably around 900 ° C.
  • the carbon fiber using cotton as a raw material is obtained by heating the cotton in an oxidizing atmosphere to infusibilization treatment or flame resistance treatment, and further heating in an inert gas for carbonization.
  • the activation function of carbon fiber can be improved by activation treatment that can be performed as activated carbon fiber having high adsorption ability by applying activation treatment.
  • a textile product according to the present invention is characterized by including the above-mentioned fibromyalgia symptom-reducing fiber according to the present invention.
  • the textile product according to the present invention for example, clothes, sheets, other bedding, cushions, carpets, sofa covers, etc., which are in contact with humans for a long time are preferable.
  • the fibromyalgia symptom-relieving fiber according to the present invention is preferably processed into a sheet and sandwiched between the fiber products according to the present invention. When processing into a sheet, it is preferable to process to a density of 1200 to 1300 gZm 2 and a thickness of about 2 to 3 mm.
  • the textile product according to the present invention is applied to one or more positions of 18 "tenderness points" of the body. This has the effect of alleviating the symptoms of fibromyalgia.
  • the degree to which it touches may be such that it touches the “tenderness point” through one or two thin fabrics such as underwear and sheets that do not need to touch the skin directly!
  • a mat according to the present invention is characterized in that the fibromyalgia symptom alleviating fiber according to the present invention is disposed in a range covering the occipital groin area of an adult.
  • the fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the mats according to the present invention.
  • processing into a sheet it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
  • the range covering from the back of the adult to the buttocks is preferably about 50 cm x 70 cm to 75 cm x 110 cm, and particularly preferably about 55 cm x 80 cm.
  • the fibromyalgia symptom-relieving fiber according to the present invention is arranged in a range that covers the occipital force of the adult up to the buttocks. Of these, (1) the occipital region, (4) the supraspinatus, and (7) the buttocks can be covered.
  • the mat according to the present invention is supine on the mat, and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, the supraspinatus, and the buttocks, thereby reducing the symptoms of fibromyalgia. It has a mitigating effect.
  • the mat according to the present invention is prone or scoliated thereon, and the fibromyalgia symptom relief fiber according to the present invention is applied to the tender point on the front side or the tender point on the side of the body.
  • the fibromyalgia symptom relief fiber according to the present invention is applied to the tender point on the front side or the tender point on the side of the body.
  • the fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the clothes according to the present invention.
  • processing into a sheet it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
  • the occipital region, lower cervical vertebrae, trapezius, supraspinatus, second gluteal muscle, lateral epicondyle, buttocks, greater trochanter and knee are 18 characteristic positions in fibromyalgia It is.
  • the garment according to the present invention is worn and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, lower cervical vertebra, trapezius, supraspinatus, second gluteal muscle, lateral epicondyle, buttocks To the greater trochanter and knee When applied, it has the effect of alleviating the symptoms of fibromyalgia.
  • the clothes according to the present invention are preferably underwear such as pants' shirts, pajamas, supporters, and scarves, but may be socks, gloves, hats, or the like.
  • the vest according to the present invention has the occipital region, the lower cervical vertebra, the trapezius, the supraspinatus, and the second ankle muscle when the fibromyalgia symptom alleviating fiber according to the present invention is worn. It is characterized by being arranged in the covered area.
  • the fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the vests according to the present invention.
  • processing into a sheet it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
  • the occipital region, lower cervical vertebrae, trapezius, supraspinatus, and second gastrocnemius are 10 positions out of the 18 “tenderness points” characteristic of fibromyalgia .
  • the vest according to the present invention has a shape in which the collar is elongated in order to apply the fibromyalgia symptom relief fiber according to the present invention to those tender points when worn.
  • the collar is elongated like a muffler so that it can be wrapped around the neck.
  • the vest according to the present invention is worn, and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, lower cervical vertebra, trapezius, supraspinatus, and second gluteal muscle, so that fibromyalgia It has the effect of relieving symptoms.
  • the emissivity of the carbon fiber usable in the present invention was measured by an infrared radiometer.
  • SA200 manufactured by Minerald
  • NEC PC-98RL a data processing device
  • the test was commissioned to Kanagawa Prefectural Industrial Technology Research Institute.
  • the test consists of a density of 1200g to 1300gZm with a density of 1200g to 1300gZm 2 (sample name: knit), a carbon fiber knitted to a thickness of 2.2mm, and a cotton-like carbon fiber processed to a thickness of 2.5mm.
  • the sheet (sample name: E- 1500), the sheet (sample name: E- 200 0) of the density 1200g to 1300 g / m 2 was Karoe to a thickness of 3 millimeters carbon fibers flocculent was performed on.
  • fibromyalgia symptoms of fibromyalgia that can be treated at any place and have no side effects. It is possible to provide fibromyalgia symptom-reducing fibers, textiles, mats, clothing, and vests that can be easily relieved.
  • FIG. 5 shows a mat according to an embodiment of the present invention.
  • the mat also has a force with the mat body 1, the cover 2, and the carbon fiber sheet 3.
  • the mat body 1 is an example and has a size of 100 cm ⁇ 200 cm ⁇ 3 cm.
  • the cover 2 is sized to cover the entire mat body 1 and has a zipper 4 at the center.
  • the cover 1 is capable of inserting and removing the mat body 1 with a zipper 4 force, and the mat body 1 is housed inside.
  • a carbon fiber sheet 3 is detachably attached to the mat body 1 with a hook-and-loop fastener at the center thereof.
  • the carbon fiber sheet 3 has a size of 75 cm ⁇ 110 cm ⁇ 0.2 cm.
  • Carbon fiber sheet 3 is manufactured by heating cotton in an acidic atmosphere at a temperature of around 900 ° C to infusibilization or flameproofing, and then heating it in an inert gas to carbonize it.
  • Commercially available products (trade name: vegetable carbon fiber organ hexa 02 sheet, manufactured by i-Tech Co., Ltd.) are used.
  • FIG. 6 shows the best of the embodiment of the present invention.
  • the vest includes a vest body 5 and a carbon fiber sheet 6.
  • the best body 5 has, for example, a collar 7 having a length of about 5 cm.
  • the vest body 5 has a double fabric, and the carbon fiber sheet 6 is sewn between the fabrics.
  • the carbon fiber sheet 6 is disposed in a range of about one third of the upper portion of the vest body 5. In other words, it is installed within 10 cm from the top edge on the front side and 17 cm from the top edge on the back side.
  • Target patients This clinical study was conducted in writing for 11 FM patients (10 women, 1 man) who met the ACR's FM classification criteria and received treatment at Sendai Yutahiro Sakura Hospital. After obtaining consent to participate in the study, it was considered as a patient for examination. This clinical trial was conducted with the approval of the Taehira Sakura Hospital Ethics Committee. The average age of the patients was 39.5 ⁇ 10.0 years old (Female: 26-49 years old, Male: 35 years old). Pharmacotherapeutic treatment for target patients ⁇ Other treatment methods should be changed from one month before participation in this study to during the study.
  • Carbon fiber sheet As a carbon fiber using cotton as a raw material, a commercial product developed by i-tech Co., Ltd. (trade name: plant carbon fiber Olga hexa 02 sheet) (80cm XI 00cm) (hereinafter, Simply called “carbon fiber sheet”).
  • Test method A carbon fiber sheet was provided to the target patients, and the shoulder line was placed at the top under the bed sheet used at bedtime, and the treatment time with carbon fiber was defined as the nighttime bedtime. The patient's bedtime followed the usual lifestyle. FM pathology was assessed using a Fibromyalgia Impact Questionnaire (FIQ) ( Figure 7)
  • FIQ Fibromyalgia Impact Questionnaire
  • the therapeutic effects of carbon fiber sheets are not only improved as assessed by the FIQ index, but in the effective cases, it is possible to get out of bedside vitality, return to work, etc.
  • the effect that contributes to the improvement of sex was also recognized.
  • the carbon fiber sheet has been observed to have a maximum effect in one hour and a short time after use. It has also been observed that the treatment effect can be easily canceled by discontinuing use.
  • Carbon fiber can exert a therapeutic effect for FM in the short term, but it is difficult to say that it is a radical therapeutic effect. Therefore, carbon fiber was used for FM treatment. Continuous treatment is necessary. It is estimated that more effective FM treatment will be possible by adopting the use of carbon fiber as the basic treatment method for FM treatment and then developing drug therapy 'diet therapy / exercise therapy'.
  • FIG. 1 is an explanatory diagram showing the position of a tender point.
  • FIG. 2 is a graph showing the results of measuring emissivity with an infrared radiometer for carbon fibers usable in the present invention.
  • FIG. 3 is a graph showing the results of measuring emissivity with an infrared radiometer for carbon fibers usable in the present invention.
  • ⁇ 4 A graph showing the results of measuring the emissivity of the carbon fiber usable in the present invention with an infrared radiometer.
  • FIG. 5 is a front view showing a mat according to an embodiment of the present invention.
  • FIG. 6 is a (A) front view and (B) rear view showing a vest according to an embodiment of the present invention.
  • FIG. 7 is an explanatory diagram showing questionnaire items regarding effects on fibromyalgia.
  • FIG. 8 is a graph showing clinical effects obtained in 1 hour after use with the carbon fiber of the present invention.
  • FIG. 9 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for one week.
  • FIG. 10 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for one week.
  • FIG. 11 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for 2 weeks.
  • FIG. 12 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for 2 weeks. 13] A graph showing the result of discontinuation of use of the carbon fiber of the present invention. Explanation of symbols

Abstract

[PROBLEMS] To provide a fiber and fiber products such as a mat, clothes and a vest which are therapeutically usable anywhere, show no side effect and can easily relieve the symptoms of fibromuscular pain. [MEANS FOR SOLVING PROBLEMS] A fiber for relieving the symptoms of fibromuscular pain which comprises a carbon fiber produced from cotton. A vest which is designed so that the fiber for relieving the symptoms of fibromuscular pain is located at the areas covering the occipital region of the head, lower cervical vertebra, trapezius muscle, supraspinous muscle and second costal muscle of a wearer.

Description

線維筋痛症の症状緩和用繊維および繊維製品  Fibromyalgia Symptom Relieving Fiber and Textile Products
技術分野  Technical field
[0001] 本発明は、線維筋痛症の症状緩和用繊維、繊維製品、マット、衣類およびべストに 関する。  [0001] The present invention relates to a fibromyalgia symptom-relieving fiber, a textile product, a mat, clothing, and a vest.
背景技術  Background art
[0002] 従来、木酢液と竹酢液の少なくとも一方を含浸させ乾燥処理して成り、抗菌性と殺 菌性とを兼ね備えた炭素繊維が開発され、注目を集めている (例えば、特許文献 1参 照)。この炭素繊維を布で被覆してシート状に形成し、このシートを中に入れた敷パッ ドゃ枕カバーも開発されている(例えば、特許文献 2, 3参照)。  [0002] Conventionally, carbon fibers which have been impregnated with at least one of wood vinegar and bamboo vinegar and dried and have both antibacterial and bactericidal properties have been developed and attract attention (for example, Patent Document 1). (See) There has also been developed a pillow pad cover in which the carbon fiber is covered with a cloth to form a sheet and the sheet is placed inside (see, for example, Patent Documents 2 and 3).
また、炭素繊維が遠赤外線を放射することから、疾患の治療や疼痛の緩和、健康 状態の改善を目的とした寝具、被服、サポーターも開発されている (例えば、特許文 献 4参照)。  In addition, because carbon fibers emit far-infrared rays, bedding, clothing, and supporters have been developed to treat diseases, reduce pain, and improve health (see, for example, Patent Document 4).
さらに、炭素繊維には、院内感染細菌に対する抗菌作用があることや、 MR信号を 遮断する効果があることが報告されている (例えば、非特許文献 1, 2参照)。  Furthermore, it has been reported that carbon fiber has an antibacterial action against nosocomial bacteria and has an effect of blocking MR signals (for example, see Non-Patent Documents 1 and 2).
[0003] 特許文献 1:特開 2000— 160476号公報 [0003] Patent Document 1: Japanese Patent Laid-Open No. 2000-160476
特許文献 2:実用新案登録第 3098293号公報  Patent Document 2: Utility Model Registration No. 3098293
特許文献 3:実用新案登録第 3095112号公報  Patent Document 3: Utility Model Registration No. 3095112
特許文献 4:特開 2004— 223188号公報  Patent Document 4: Japanese Unexamined Patent Application Publication No. 2004-223188
非特許文献 1 :第 81回 日本細菌学会関東支部総会 講演抄録集  Non-Patent Document 1: The 81st Annual Meeting of the Kanto Branch of the Bacteriological Society of Japan
非特許文献 2 :第 10回 日本血管内治療学会総会 プログラム ·抄録集  Non-Patent Document 2: 10th Annual Meeting of the Japanese Endovascular Society Program
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0004] 近年、線維筋痛症が原因不明の疾患として問題となっている。線維筋痛症は、身 体の全身または局所に痛み、痺れなどを生じ、不眠、頭痛、微熱、疲労感などを伴う 疾患である。 [0004] In recent years, fibromyalgia has become a problem as an unknown disease. Fibromyalgia is a disease that causes pain, numbness, etc. throughout the body or area of the body, and is accompanied by insomnia, headache, slight fever, and fatigue.
線維筋痛症の症状を表 1に示す。 [表 1] 線維筋痛症の症状 Table 1 shows the symptoms of fibromyalgia. [Table 1] Fibromyalgia symptoms
Figure imgf000004_0001
現在、治療方法として、頸部の星状神経節を注射または低出力レベルレーザーで ブロックする方法や、抗不安薬、抗うつ薬、抗てんかん薬などの薬剤を服用する方法 が採用されている。
Figure imgf000004_0001
Currently, treatment methods include blocking cervical stellate ganglia by injection or low-power laser, and taking drugs such as anti-anxiety drugs, antidepressants, and antiepileptic drugs.
[0005] し力しながら、注射やレーザー照射、薬剤投与には熟練した技術が必要であること から、治療場所が限定されるという課題があった。また、薬剤の服用には、副作用の おそれ力 Sあるという課題もあった。線維筋痛症は根本原因が不明であり、完全な治療 方法が確立していないことから、薬剤を長期間、服用し続ける必要がある。このため、 副作用のおそれも高かった。  [0005] However, there is a problem that the treatment place is limited because skilled techniques are required for injection, laser irradiation, and drug administration. In addition, there is a problem that taking drugs has the potential for side effects. Since the root cause of fibromyalgia is unknown and a complete treatment method has not been established, it is necessary to continue taking the drug for a long period of time. For this reason, there was a high risk of side effects.
[0006] 本発明は、このような課題に着目してなされたもので、場所を選ばずに治療可能で 、副作用がなぐ線維筋痛症の症状を手軽に緩和することができる線維筋痛症の症 状緩和用繊維、繊維製品、マット、衣類およびべストを提供することを目的としている 課題を解決するための手段 [0006] The present invention has been made paying attention to such a problem, and can be treated regardless of location, and can easily relieve the symptoms of fibromyalgia without side effects. Symptoms of Means for solving the problems aimed at providing fibers, textiles, mats, clothing and vests
[0007] 上記目的を達成するために、本発明に係る線維筋痛症の症状緩和用繊維は、綿 花を原料とする炭素繊維から成ることを特徴とする。 [0007] In order to achieve the above object, the fibromyalgia symptom alleviating fiber according to the present invention is composed of carbon fiber made of cotton.
本発明に係る線維筋痛症の症状緩和用繊維は、シート状に加工されて!ヽることが 好ましい。シート状にカ卩ェする方法としては、例えば、編む方法、不織布その他の 2 枚の布の間に挟み込む方法、布の袋の中に封入する方法が好ましい。シートに加工 する場合、密度 1200g乃至 1300gZm2、厚さ 2ミリ乃至 3ミリ程度に加工することが 好ましい。 The fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet shape. As a method for forming a sheet, for example, a knitting method, a non-woven fabric or other method of sandwiching between two cloths, and a method of enclosing in a cloth bag are preferable. When processing into a sheet, it is preferable to process to a density of 1200 to 1300 gZm 2 and a thickness of about 2 to 3 mm.
[0008] 本発明に係る線維筋痛症の症状緩和用繊維は、身体の 18個所の「圧痛点」の位 置にできるだけ近づけて配置することにより、線維筋痛症の症状を緩和する効果があ る。近づける程度は、直接、肌に触れさせなくてもよぐ肌着やシーツなど 1枚、 2枚程 度の薄 、生地越しに「圧痛点」に当てる程度であってもよ 、。  [0008] The fibromyalgia symptom alleviating fiber according to the present invention has an effect of relieving fibromyalgia symptom by being placed as close as possible to the positions of 18 "tenderness points" on the body. is there. The degree of closeness may be as small as one or two underwear or sheets that do not need to be touched directly on the skin, or just touch the “tenderness point” through the fabric.
[0009] 「圧痛点」は、身体の両側に対称に存在し、約 4kgの強さで触診を行ったとき、「痛く ない」、「少し痛い」、「中くらいに痛い」および「とても痛い」の 4段階で、「少し痛い」以 上に感じる個所である。後頭部、下部頸椎、僧帽筋、棘上筋、第二肋筋、外側上顆、 臀部、大転子および膝が、線維筋痛症における特徴的な「圧痛点」の位置である。よ り具体的には、(1)後頭部:後頭下筋の腱付、(2)下部頸椎:第 5〜7頸椎間の前方、 (3)僧帽筋:上縁の中央部、(4)棘上筋:起始部、内縁に近いところで肩甲骨棘部の 上、(5)第二肋筋:第二肋骨一肋軟骨結合部、結合部のすぐ外側、(6)外側上顆: 上頼から 2cm遠位、(7)臀部:臀部の 4半上外側部、(8)大転子:転子突起の後部、 (9)膝:内側やや上部のふつくらした部分のそれぞれ 1対の個所が圧痛点である。圧 痛点の位置を図 1に示す。  [0009] "Tender point" exists symmetrically on both sides of the body, and when palpated at a strength of about 4kg, "not painful", "slightly painful", "moderately painful" and "very painful" In the four stages of "", it is the part that feels more than "a little painful". The occipital region, lower cervical vertebrae, trapezius, supraspinatus, second gastrocnemius, lateral epicondyle, buttocks, greater trochanter and knee are the characteristic “tender point” positions in fibromyalgia. More specifically, (1) the occipital region: with the suboccipital tendon, (2) the lower cervical vertebra: anterior between the 5th and 7th cervical vertebrae, (3) the trapezius: the middle of the upper edge, (4) Supraspinous muscle: origin, above the scapula spine near the inner edge, (5) second gluteal muscle: second rib-one costal cartilage joint, just outside the joint, (6) lateral epicondyle: upper 2cm distal from the Yori, (7) buttocks: 4 semi-upper outer side of the buttocks, (8) greater trochanter: posterior part of the trochanter, (9) knee: a pair of fluffy parts on the inside and slightly above The place is the tender point. Figure 1 shows the location of the tender point.
[0010] 本発明に係る線維筋痛症の症状緩和用繊維は、 18個所の「圧痛点」のすべてに 同時に当てた状態を維持し続けることが症状緩和効果を高め、持続させるうえで好ま しい。さらに、全身を覆うことが好ましい。しかしながら、「圧痛点」のいずれか 1個所の みに当てて使用した場合にも、線維筋痛症の症状緩和効果が認められる。「圧痛点」 以外の痛む個所に当ててもよい。また、常に当て続けなくてもよぐ 日中だけの使用ま たは夜間だけの使用でも使用して 、な ヽ間の症状緩和効果が認められる。 [0010] For the fibromyalgia symptom alleviating fiber according to the present invention, it is preferable to maintain and apply the condition simultaneously applied to all of the 18 “tenderness points” in order to enhance and sustain the symptom relief effect. . Furthermore, it is preferable to cover the whole body. However, the effect of relieving the symptoms of fibromyalgia is also observed when used on only one of the “tenderness points”. "Tender point" It may be applied to other painful places. In addition, it does not always need to be applied, and it can be used only during the daytime or only during the nighttime.
[0011] 本発明に係る線維筋痛症の症状緩和用繊維は、場所を選ばずに治療可能で、副 作用がなぐ線維筋痛症の症状を手軽に緩和することができる。  [0011] The fibromyalgia symptom alleviating fiber according to the present invention can be treated at any place, and can easily relieve the fibromyalgia symptom without side effects.
本発明に係る線維筋痛症の症状緩和用繊維の作用機序は不明である。炭素繊維 には、遠赤外線放射効果があることが知られているが、遠赤外線放射のみでは線維 筋痛症の症状への影響は小さいため、炭素繊維による遠赤外線放射と他の電磁波 放射との相乗効果と考えられる。  The mechanism of action of the fibromyalgia symptom relief fiber according to the present invention is unknown. Carbon fiber is known to have a far-infrared radiation effect, but far-infrared radiation alone has little effect on the symptoms of fibromyalgia. It is considered a synergistic effect.
[0012] 本発明に係る線維筋痛症の症状緩和用繊維は、木酢液、竹酢液またはその両方 を主成分とする処理液を、綿花を原料とする炭素繊維に含浸'乾燥させて成ることが 好ましい。この場合、殺菌性'抗菌性を得ることができる。処理液には、ョモギエキスを 含有させてあってもよい。含浸方法としては、浸漬が好ましい。この場合、浸漬処理し た炭素繊維を蒸留水で洗浄した後、乾燥させることが好ましい。乾燥方法としては、 真空乾燥または温風乾燥が好ま 、。  [0012] The fibromyalgia symptom-relieving fiber according to the present invention is obtained by impregnating and drying a treatment liquid mainly composed of wood vinegar, bamboo vinegar, or both into cotton fibers. It is preferable. In this case, bactericidal and antibacterial properties can be obtained. The processing solution may contain mugwort extract. As the impregnation method, immersion is preferred. In this case, it is preferable to wash the carbon fiber soaked with distilled water and then dry it. As the drying method, vacuum drying or hot air drying is preferred.
[0013] 本発明に係る線維筋痛症の症状緩和用繊維は、綿花を原料とする炭素繊維に限 定される。綿花を原料とする炭素繊維は、綿花を 800°C以上、好ましくは 900°C前後 の高温で炭化させたものが好ましい。特に、綿花を原料とする炭素繊維は、綿花を酸 化雰囲気中で加熱して不融化処理または耐炎化処理を施し、さらに不活性ガス中で 加熱し炭素化して成ることが好ましい。炭素繊維は、賦活処理を施して吸着能の高い 活性炭素繊維としてもよぐ賦活処理により遠赤外線の放射機能を向上させることが できる。  [0013] The fibromyalgia symptom alleviating fiber according to the present invention is limited to carbon fiber made from cotton. Carbon fibers made from cotton are preferably carbonized carbonized at a high temperature of 800 ° C or higher, preferably around 900 ° C. In particular, it is preferable that the carbon fiber using cotton as a raw material is obtained by heating the cotton in an oxidizing atmosphere to infusibilization treatment or flame resistance treatment, and further heating in an inert gas for carbonization. The activation function of carbon fiber can be improved by activation treatment that can be performed as activated carbon fiber having high adsorption ability by applying activation treatment.
[0014] 本発明に係る繊維製品は、前述の本発明に係る線維筋痛症の症状緩和用繊維を 含むことを特徴とする。本発明に係る繊維製品としては、例えば、衣類、シーツその 他の寝具、座布団、じゅうたん、ソファーカバーなど、人が長時間、接触するものが好 ましい。本発明に係る線維筋痛症の症状緩和用繊維は、シート状に加工されて、本 発明に係る繊維製品の中に挟み込まれて 、ることが好まし 、。シートに加工する場合 、密度 1200g乃至 1300gZm2、厚さ 2ミリ乃至 3ミリ程度に加工することが好ましい。 [0014] A textile product according to the present invention is characterized by including the above-mentioned fibromyalgia symptom-reducing fiber according to the present invention. As the textile product according to the present invention, for example, clothes, sheets, other bedding, cushions, carpets, sofa covers, etc., which are in contact with humans for a long time are preferable. The fibromyalgia symptom-relieving fiber according to the present invention is preferably processed into a sheet and sandwiched between the fiber products according to the present invention. When processing into a sheet, it is preferable to process to a density of 1200 to 1300 gZm 2 and a thickness of about 2 to 3 mm.
[0015] 本発明に係る繊維製品は、身体の 18個所の「圧痛点」の 1個所以上の位置に当て ることにより、線維筋痛症の症状を緩和する効果がある。当てる程度は、直接、肌に 触れさせなくてもよぐ肌着やシーツなど 1枚、 2枚程度の薄い生地越しに「圧痛点」 に当てる程度であってもよ!/、。 [0015] The textile product according to the present invention is applied to one or more positions of 18 "tenderness points" of the body. This has the effect of alleviating the symptoms of fibromyalgia. The degree to which it touches may be such that it touches the “tenderness point” through one or two thin fabrics such as underwear and sheets that do not need to touch the skin directly!
[0016] 本発明に係るマットは、前述の本発明に係る線維筋痛症の症状緩和用繊維を成人 の後頭部力 臀部までを覆う範囲に配置して成ることを特徴とする。  [0016] A mat according to the present invention is characterized in that the fibromyalgia symptom alleviating fiber according to the present invention is disposed in a range covering the occipital groin area of an adult.
本発明に係る線維筋痛症の症状緩和用繊維は、シート状に加工されて、本発明に 係るマットの中に挟み込まれていることが好ましい。シートに加工する場合、密度 120 Og乃至 1300gZm2、厚さ 2ミリ乃至 3ミリ程度に加工することが好ましい。 The fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the mats according to the present invention. When processing into a sheet, it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
成人の後頭部から臀部までを覆う範囲としては、 50cm X 70cm乃至 75cm X 110c m程度の大きさが好ましぐ特に 55cm X 80cm程度の大きさが好ましい。本発明に 係るマットは、本発明に係る線維筋痛症の症状緩和用繊維を成人の後頭部力も臀部 までを覆う範囲に配置してあるため、成人が仰臥したとき、前述の 18個所の圧痛点の うち、(1)後頭部、(4)棘上筋、および (7)臀部を覆うことができる。  The range covering from the back of the adult to the buttocks is preferably about 50 cm x 70 cm to 75 cm x 110 cm, and particularly preferably about 55 cm x 80 cm. In the mat according to the present invention, the fibromyalgia symptom-relieving fiber according to the present invention is arranged in a range that covers the occipital force of the adult up to the buttocks. Of these, (1) the occipital region, (4) the supraspinatus, and (7) the buttocks can be covered.
[0017] 本発明に係るマットは、その上に仰臥して、本発明に係る線維筋痛症の症状緩和 用繊維を後頭部、棘上筋および臀部に当てることにより、線維筋痛症の症状を緩和 する効果がある。なお、本発明に係るマットは、その上に伏臥または側臥して、本発 明に係る線維筋痛症の症状緩和用繊維を身体の正面側の圧痛点または側面側の 圧痛点に当てるようにしてもょ 、。  [0017] The mat according to the present invention is supine on the mat, and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, the supraspinatus, and the buttocks, thereby reducing the symptoms of fibromyalgia. It has a mitigating effect. The mat according to the present invention is prone or scoliated thereon, and the fibromyalgia symptom relief fiber according to the present invention is applied to the tender point on the front side or the tender point on the side of the body. Well, ...
[0018] 本発明に係る衣類は、前述の本発明に係る線維筋痛症の症状緩和用繊維を、着 用したとき、後頭部、下部頸椎、僧帽筋、棘上筋、第二肋筋、外側上顆、臀部、大転 子および膝を覆う範囲に配置して成ることを特徴とする。  [0018] When the garment according to the present invention is used for the fibromyalgia symptom alleviating fiber according to the present invention, the occipital region, the lower cervical vertebra, the trapezius, the supraspinatus, the second ankle, It is arranged to cover the lateral epicondyle, buttocks, greater trochanter and knee.
本発明に係る線維筋痛症の症状緩和用繊維は、シート状に加工されて、本発明に 係る衣類の中に挟み込まれていることが好ましい。シートに加工する場合、密度 120 Og乃至 1300gZm2、厚さ 2ミリ乃至 3ミリ程度に加工することが好ましい。 The fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the clothes according to the present invention. When processing into a sheet, it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
[0019] 前述のとおり、後頭部、下部頸椎、僧帽筋、棘上筋、第二肋筋、外側上顆、臀部、 大転子および膝は、線維筋痛症における特徴的な 18個所の位置である。  [0019] As mentioned above, the occipital region, lower cervical vertebrae, trapezius, supraspinatus, second gluteal muscle, lateral epicondyle, buttocks, greater trochanter and knee are 18 characteristic positions in fibromyalgia It is.
本発明に係る衣類は、着用して、本発明に係る線維筋痛症の症状緩和用繊維を後 頭部、下部頸椎、僧帽筋、棘上筋、第二肋筋、外側上顆、臀部、大転子および膝に 当てることにより、線維筋痛症の症状を緩和する効果がある。 The garment according to the present invention is worn and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, lower cervical vertebra, trapezius, supraspinatus, second gluteal muscle, lateral epicondyle, buttocks To the greater trochanter and knee When applied, it has the effect of alleviating the symptoms of fibromyalgia.
本発明に係る衣類としては、例えば、パンツ'シャツなどの肌着、パジャマ、サポー ター、スカーフが好ましいが、靴下や手袋、帽子などであってもよい。  The clothes according to the present invention are preferably underwear such as pants' shirts, pajamas, supporters, and scarves, but may be socks, gloves, hats, or the like.
[0020] 本発明に係るベストは、前述の本発明に係る線維筋痛症の症状緩和用繊維を、着 用したとき、後頭部、下部頸椎、僧帽筋、棘上筋および第二肋筋を覆う範囲に配置し て成ることを特徴とする。  [0020] The vest according to the present invention has the occipital region, the lower cervical vertebra, the trapezius, the supraspinatus, and the second ankle muscle when the fibromyalgia symptom alleviating fiber according to the present invention is worn. It is characterized by being arranged in the covered area.
本発明に係る線維筋痛症の症状緩和用繊維は、シート状に加工されて、本発明に 係るベストの中に挟み込まれていることが好ましい。シートに加工する場合、密度 120 Og乃至 1300gZm2、厚さ 2ミリ乃至 3ミリ程度に加工することが好ましい。 The fibromyalgia symptom alleviating fiber according to the present invention is preferably processed into a sheet and sandwiched between the vests according to the present invention. When processing into a sheet, it is preferable to process to a density of 120 Og to 1300 gZm 2 and a thickness of about 2 mm to 3 mm.
[0021] 前述のとおり、後頭部、下部頸椎、僧帽筋、棘上筋および第二肋筋は、線維筋痛 症における特徴的な 18個所の「圧痛点」のうちの 10箇所の位置である。本発明に係 るべストは、着用したとき本発明に係る線維筋痛症の症状緩和用繊維をそれらの圧 痛点に当てるため、襟が長く伸びた形状を有する。その襟の部分は、マフラーのよう に首に巻き付け可能に細長く伸びて 、てもよ 、。  [0021] As mentioned above, the occipital region, lower cervical vertebrae, trapezius, supraspinatus, and second gastrocnemius are 10 positions out of the 18 “tenderness points” characteristic of fibromyalgia . The vest according to the present invention has a shape in which the collar is elongated in order to apply the fibromyalgia symptom relief fiber according to the present invention to those tender points when worn. The collar is elongated like a muffler so that it can be wrapped around the neck.
本発明に係るベストは、着用して、本発明に係る線維筋痛症の症状緩和用繊維を 後頭部、下部頸椎、僧帽筋、棘上筋および第二肋筋に当てることにより、線維筋痛症 の症状を緩和する効果がある。  The vest according to the present invention is worn, and the fibromyalgia symptom alleviating fiber according to the present invention is applied to the occipital region, lower cervical vertebra, trapezius, supraspinatus, and second gluteal muscle, so that fibromyalgia It has the effect of relieving symptoms.
[0022] 本発明で使用可能な炭素繊維について、赤外線放射計により放射率を測定した。  [0022] The emissivity of the carbon fiber usable in the present invention was measured by an infrared radiometer.
赤外線放射計には、市販製品(ミネラッド社製 SA200)を使用した。データ処理装 置 (NEC社製 PC- 98RL)によりデータ解析を行った。試験は、神奈川県産業技 術総合研究所に依頼して行った。試験は、炭素繊維を厚さ 2. 2ミリに編んで成る密 度 1200g乃至 1300gZm2のシート (試料名:ニット)、綿状の炭素繊維を厚さ 2. 5ミリ に加工した密度 1200g乃至 1300gZm2のシート(試料名: E— 1500)、綿状の炭素 繊維を厚さ 3ミリにカロェした密度 1200g乃至 1300g/m2のシート(試料名: E— 200 0)について行った。 A commercially available product (SA200 manufactured by Minerald) was used for the infrared radiometer. Data analysis was performed using a data processing device (NEC PC-98RL). The test was commissioned to Kanagawa Prefectural Industrial Technology Research Institute. The test consists of a density of 1200g to 1300gZm with a density of 1200g to 1300gZm 2 (sample name: knit), a carbon fiber knitted to a thickness of 2.2mm, and a cotton-like carbon fiber processed to a thickness of 2.5mm. 2 of the sheet (sample name: E- 1500), the sheet (sample name: E- 200 0) of the density 1200g to 1300 g / m 2 was Karoe to a thickness of 3 millimeters carbon fibers flocculent was performed on.
それらの結果を図 2乃至図 4に示す。  The results are shown in Figs.
発明の効果  The invention's effect
[0023] 本発明によれば、場所を選ばずに治療可能で、副作用がなぐ線維筋痛症の症状 を手軽に緩和することができる線維筋痛症の症状緩和用繊維、繊維製品、マット、衣 類およびべストを提供することができる。 [0023] According to the present invention, symptoms of fibromyalgia that can be treated at any place and have no side effects. It is possible to provide fibromyalgia symptom-reducing fibers, textiles, mats, clothing, and vests that can be easily relieved.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0024] 以下、図面に基づき、本発明の実施の形態について説明する。  Hereinafter, embodiments of the present invention will be described with reference to the drawings.
図 5は、本発明の実施の形態のマットを示している。  FIG. 5 shows a mat according to an embodiment of the present invention.
図 5に示すように、マットは、マット本体 1と、カバー 2と、炭素繊維シート 3と力も成つ ている。マット本体 1は、一例で、 100cm X 200cm X 3cmの大きさである。カバー 2 は、マット本体 1の全体を覆う大きさから成り、中央部にジッパー 4を有している。カバ 一 2は、ジッパー 4力 マット本体 1を出し入れ可能であり、内部にマット本体 1を収納 している。マット本体 1には、その中央部に炭素繊維シート 3が面ファスナーで着脱可 能に貼り付けられている。炭素繊維シート 3は、一例で、 75cm X 110cm X 0. 2cm の大きさである。炭素繊維シート 3には、綿花を、酸ィ匕雰囲気中で 900°C前後の温度 で加熱して不融化処理または耐炎化処理を施し、さらに不活性ガス中で加熱して炭 素化し、製造した市販の製品 (ィーテック株式会社製、商品名:植物性炭素繊維オル ガへキサ 02シート)を用いる。  As shown in FIG. 5, the mat also has a force with the mat body 1, the cover 2, and the carbon fiber sheet 3. The mat body 1 is an example and has a size of 100 cm × 200 cm × 3 cm. The cover 2 is sized to cover the entire mat body 1 and has a zipper 4 at the center. The cover 1 is capable of inserting and removing the mat body 1 with a zipper 4 force, and the mat body 1 is housed inside. A carbon fiber sheet 3 is detachably attached to the mat body 1 with a hook-and-loop fastener at the center thereof. For example, the carbon fiber sheet 3 has a size of 75 cm × 110 cm × 0.2 cm. Carbon fiber sheet 3 is manufactured by heating cotton in an acidic atmosphere at a temperature of around 900 ° C to infusibilization or flameproofing, and then heating it in an inert gas to carbonize it. Commercially available products (trade name: vegetable carbon fiber organ hexa 02 sheet, manufactured by i-Tech Co., Ltd.) are used.
[0025] 図 6は、本発明の実施の形態のベストを示している。 [0025] FIG. 6 shows the best of the embodiment of the present invention.
図 6に示すように、ベストは、ベスト本体 5と、炭素繊維シート 6とから成っている。ベ スト本体 5は、一例で約 5cmの長さの襟 7を有している。ベスト本体 5は生地が 2重に なっており、炭素繊維シート 6はその生地の間に挟み込まれて縫い付けられている。 炭素繊維シート 6は、ベスト本体 5の上部約 3分の 1の範囲に配置されている。すなわ ち、正面側で上端から 10cm、背面側で上端から 17cmの範囲に取り付けられている  As shown in FIG. 6, the vest includes a vest body 5 and a carbon fiber sheet 6. The best body 5 has, for example, a collar 7 having a length of about 5 cm. The vest body 5 has a double fabric, and the carbon fiber sheet 6 is sewn between the fabrics. The carbon fiber sheet 6 is disposed in a range of about one third of the upper portion of the vest body 5. In other words, it is installed within 10 cm from the top edge on the front side and 17 cm from the top edge on the back side.
[0026] [炭素繊維による線維筋痛症の症状緩和効果] [0026] [Symptom relief effect of fibromyalgia by carbon fiber]
[試験方法]  [Test method]
(1)対象患者:仙台巿太白さくら病院で通院治療を受けている、 ACRの FM分類基準 を満たす FM患者 11名(女性: 10名、男性: 1名)に対して、文書にて本臨床試験への 参加承諾を取得した後検討対象患者とした。本臨床試験は太白さくら病院倫理委員 会の承認の元に行なわれた。対象患者の平均年齢は 39.5 ± 10.0歳(女性: 26-49歳、 男性: 35歳)であった。対象患者への薬物療法 ·その他の治療方法は本試験参加一 ヶ月前から試験中に至るまで一切変更を加えて ヽな 、。 (1) Target patients: This clinical study was conducted in writing for 11 FM patients (10 women, 1 man) who met the ACR's FM classification criteria and received treatment at Sendai Yutahiro Sakura Hospital. After obtaining consent to participate in the study, it was considered as a patient for examination. This clinical trial was conducted with the approval of the Taehira Sakura Hospital Ethics Committee. The average age of the patients was 39.5 ± 10.0 years old (Female: 26-49 years old, Male: 35 years old). Pharmacotherapeutic treatment for target patients · Other treatment methods should be changed from one month before participation in this study to during the study.
(2)炭素繊維シート:本試験では、綿花を原料とする炭素繊維として、ィーテック株式 会社の開発した市販品(商品名:植物性炭素繊維オルガへキサ 02シート) (80cm X I 00cm) (以下、単に「炭素繊維シート」という)を用いた。  (2) Carbon fiber sheet: In this test, as a carbon fiber using cotton as a raw material, a commercial product developed by i-tech Co., Ltd. (trade name: plant carbon fiber Olga hexa 02 sheet) (80cm XI 00cm) (hereinafter, Simply called “carbon fiber sheet”).
(3)試験方法:炭素繊維シートを対象患者に提供し、就寝時に使用するベッドシーツ の下に、肩峰ラインを上端として敷き、夜間就寝時間中をもって炭素繊維による治療 時間と規定した。対象患者の就寝時間は普段の生活習慣を踏襲した。 FMの病勢は アンケート(Fibromyalgia Impact Questionnaire) (FIQ) (図 7)を用いて評価を行なった  (3) Test method: A carbon fiber sheet was provided to the target patients, and the shoulder line was placed at the top under the bed sheet used at bedtime, and the treatment time with carbon fiber was defined as the nighttime bedtime. The patient's bedtime followed the usual lifestyle. FM pathology was assessed using a Fibromyalgia Impact Questionnaire (FIQ) (Figure 7)
[0027] 一次調査:エントリ一順で 6位までの症例 (女性 6名:平均年齢 36歳)につ 、て、炭素 繊維シート使用 1時間後の症状変化について FIQ項目中の「痛み (Pain)」、「疲労 (Fa tigue)」、「気分(Tiredness)」、「こわばり (Stiffhess)」を観察した。 [0027] Primary survey: Cases up to 6th place in the order of entries (6 women: average age 36 years old) About the change in symptoms 1 hour after using carbon fiber sheet “Pain” in FIQ item "Fatigue", "Tiredness" and "Stiffhess" were observed.
二次調査:調査全症例 11例につ 、て炭素繊維シートを一週間使用し、 FIQによる評 価を行った。三次調査:調査対象症例で、炭素繊維シートの継続使用を行い、 FIQに よる評価を観察し得た 7例 (女性 7名:平均年齢 38.4歳)について炭素繊維シート使用 二週間目での評価を行った。  Secondary survey: Eleven cases surveyed were evaluated by FIQ using carbon fiber sheets for a week. Third survey: Seven patients (seven women: average age 38.4 years) who were able to observe the evaluation by FIQ after continuous use of the carbon fiber sheet in the surveyed cases were evaluated at the second week of using the carbon fiber sheet. went.
特別調査:調査対象症例中 1例 (女性: 41歳)については本人の同意の下に、炭素 繊維シート二日間使用した後、二週間の炭素繊維シート非使用期間をおき、 FIQに よる評価を行った。この症例については、特別調査の後に一次調査以降に参加して bらつた。  Special Survey: One case (female: 41 years old) of the surveyed subjects, after using the carbon fiber sheet for 2 days with the consent of the person, was given a 2-week non-use period for the carbon fiber sheet, and evaluated by FIQ. went. For this case, we participated in the first and subsequent surveys after the special survey.
[0028] [結果]  [0028] [Result]
( 1)一次調査結果:炭素繊維シートによる速やかなる臨床症状の改善が認められた。 炭素繊維シート使用後一時間で得られる臨床効果を、 FIQ項目中、短時間評価が 可能な四項目(痛み ·疲労感 ·気分 'こわばり)について評価したところ、全例におい て悪化は認められず、疲労感 ·気分では全例力 S1時間で改善が認められた。その結 果を図 8に示す。各項目とも有意に改善効果が得られ、特に疲労感'気分における 改善は大きな有意差をもって効果が認められた。その結果を表 2に示す。 [表 2] 炭素繊維シー 卜の短時間効果 (1) Primary survey results: A rapid improvement in clinical symptoms was observed with the carbon fiber sheet. When the clinical effects obtained in one hour after using the carbon fiber sheet were evaluated for four items (pain, fatigue, mood “stiffness”) that could be evaluated for a short time in the FIQ items, no deterioration was observed in all cases. In the case of fatigue and mood, improvement was observed in all cases with a strength of S1 hour. Figure 8 shows the result. A significant improvement effect was obtained for each item, and in particular, an improvement in fatigue feeling was found with a significant difference. The results are shown in Table 2. [Table 2] Short-term effect of carbon fiber sheet
6名(女性 6名) 使用前 1時間後 Ρ値, 年齢: 3B.0±11·4 平均値土標準偏差 平均値土標準偏差 paired  6 people (6 women) 1 hour before use Ρ value, age: 3B.0 ± 11 · 4 Average soil standard deviation Average soil standard deviation paired
5.3±3.4 3·8±3·3 ρ<0.05 咸 7.3±2.9 3·5±2·0 ρ<0.005 気分 7.3±3·3 2·8±1.9 ρ<0.01 こわばり 4.2±4· 1 2·2±2.1 ρ<0.05 5.3 ± 3.4 3 ・ 8 ± 3 ・ 3 ρ <0.05 7.3 7.3 ± 2.9 3 ・ 5 ± 2 ・ 0 ρ <0.005 Mood 7.3 ± 3 ・ 3 2 ・ 8 ± 1.9 ρ <0.01 Stiffness 4.2 ± 4 ・ 1 2 ・ 2 ± 2.1 ρ <0.05
[0029] (2)二次調査結果:炭素繊維シートの一週間使用により有意に FIQ指数が改善した。 [0029] (2) Results of secondary survey: FIQ index was significantly improved by using carbon fiber sheets for a week.
炭素繊維シート使用全例において一週間使用後の臨床効果を FIQにて評価を行 つた。炭素繊維シート使用前の平均 FIQ指数は 73.2、炭素繊維シート使用一週間目 の平均 FIQ指数は 52.9であり、炭素繊維シート使用一週間目での FIQ降下率は 27.5 ±15.0%であった。 FIQ指数の改善は ρく 0.0005と大きな有意差が得られた。 FIQ項目 中、「身体動作 (Physical impairment)」、「休業(Work missed)」では有意な改善が得 られなかった。(図 9、図 10、表 3参照)。  In all patients using carbon fiber sheets, the clinical effects after one week of use were evaluated by FIQ. The average FIQ index before using the carbon fiber sheet was 73.2, the average FIQ index after using the carbon fiber sheet was 52.9, and the FIQ drop rate after using the carbon fiber sheet was 27.5 ± 15.0%. The improvement of the FIQ index was a significant difference with ρ 0.0005. Among FIQ items, “physical impairment” and “work missed” did not improve significantly. (See Figure 9, Figure 10, Table 3.)
[0030] [表 3] [0030] [Table 3]
炭素繊維シー卜の 1週間継続効果 Continuous effect of carbon fiber sea bream for 1 week
11名(男性 1名,女性 10名) 使用前 1通間後 Ρ値, 年齡 :39.5±10.0 平均 «土標率偏差 平均値 ±標準偏差 paired 身体的陣害の程度 5.9±2·6 5.2±3.0 N. S. 11 people (1 male, 10 females) Before use 1 day after use Ρ value, annual salary: 39.5 ± 10.0 average «Soil deviation rate average value ± standard deviation paired Degree of physical harm 5.9 ± 2.6 6 ± 3.0 NS
気分の悪さ 8.6±1.8 6.1±2.5 pく 0.01 仕事や家事の休み度 3.6±3.3 3.1±3.0 N. S.  Mood 8.6 ± 1.8 6.1 ± 2.5 p 0.01 Free time for work or housework 3.6 ± 3.3 3.1 ± 3.0 N.S.
仕事や家事が妨げられた程度 6.6±2.7 5.0±2.8 p<0.005  Degree of interference with work or housework 6.6 ± 2.7 5.0 ± 2.8 p <0.005
7.5±1.5 5.1±2.4 p<0.005 疲労感 8.9±1.0 6.8±2.2 p<0.01 起床時の気分 8.5±2.0 4.7±2.5 p<0.005 こわばり 1 ±1.1 4. Β±2.8 p<0.005 不安感 Β·4±1·7 6.4±2.9 p<0.01 落ち込みの程度 7. Β±2· 0 5. Β±2.9 pく 0.01 7.5 ± 1.5 5.1 ± 2.4 p <0.005 Fatigue 8.9 ± 1.0 6.8 ± 2.2 p <0.01 Wake-up 8.5 ± 2.0 4.7 ± 2.5 p <0.005 Stiffness 1 ± 1.1 4. Β ± 2.8 p <0.005 Anxiety Β4 ± 1 · 7 6.4 ± 2.9 p <0.01 Degree of depression 7.Β ± 2 · 0 5.Β ± 2.9 p 0.01
FIQ合計得点 73.2±11.4 52.9±13·5 pく 0.0005 FIQ total score 73.2 ± 11.4 52.9 ± 13.5 p 0.0005
(3)三次調査結果:炭素繊維シートの二週間使用により有意な FIQ指数の改善は得 られたものの、 FIQ項目の一部では増悪例も認められた。 (3) Results of the third survey: Although a significant improvement in the FIQ index was obtained by using carbon fiber sheets for two weeks, there were some exacerbations in some FIQ items.
炭素繊維シート継続使用 7例にお 、て二週間使用後の臨床効果を FIQにて評価を 行った。炭素繊維シート使用前の平均 FIQ指数は 76.7、炭素繊維シート使用二週間 目の平均 FIQ指数は 41.2であり、炭素繊維シート使用二週間目での FIQ降下率は 46. 1 ±25.5%であった。 FIQ指数の改善は pく 0.005と有意であった。 FIQ項目中「休業」 では有意な改善が得られな力つた。また、「休業」以外の FIQ項目では有意な改善が 得られたものの、「身体動作」、「不快 (Feel Bad)」、「労作能力(Job ability)」、「疼痛」 、「疲労感」、「気分」、「こわばり」、「不安感 (Anxiety)」では増悪例が認められた。「落 ち込み(Depression) では増悪例は認められなかった(図 11、図 12、表 4参照)。  In 7 cases of continuous use of carbon fiber sheets, the clinical effects after 2 weeks of use were evaluated by FIQ. The average FIQ index before using carbon fiber sheets was 76.7, the average FIQ index after using carbon fiber sheets was 41.2, and the FIQ drop rate after using carbon fiber sheets was 46.1 ± 25.5%. . The improvement of the FIQ index was significant at 0.005. Of the FIQ items, “No work” was not able to achieve a significant improvement. Although there was significant improvement in FIQ items other than “absence”, “physical movement”, “Feel Bad”, “Job ability”, “pain”, “feeling of fatigue” Exacerbated cases were observed in “feeling”, “stiffness”, and “Anxiety”. “There were no exacerbations in Depression (see Figures 11, 12, and Table 4).
[表 4] 炭素繊維シー卜の 2週間継続効果 [Table 4] Continuous effect of carbon fiber sheet for 2 weeks
使用前 2週間後 D /ar r 平均値土標準偏差 1暹間後 平均僮士標準偏差 Ρ値'
Figure imgf000013_0001
5 平均値 ±標準偏差 pa ed 身体的障害の程度 7. 1 ±2. 0 5. 9±3. 0 4. 2±3. 3 ρ<0. 01 気分の恶さ 8. 6±2. 2 5. 5±2. 5 5. 3±3. 6 ρ<0. 01 仕事や家事の休み度 4. 5±3. 6 4. 1 ±3· 2 3. 3±3. 7 N. S. 仕事や家事が妨げられた程度 7. 4±2. 2 5. 4±2. 4 4. 3±2· Β ρ<0. 01 痛み B. 4±0. B 5. 4±2. 1 4. 6±1. 9 ρ<0. 005 疲労感 9. 0±0. 8 6. 1 ±2. 6 5. 3±3. 3 ρ<0. 01 起床時の気分 8. 0±2. 2 4. 7±2. 7 3. 7±2. 6 ρく 0. 05 こわばり 8. 3±1. 0 4. 9±2. 3 4. 3±3. 1 ρ<0. 05 不安感 8. 0±2· 0 5. 1 ±2. 9 3. 4±2· 3 ρ<0. 005 落ち込みの程度 7. 4±2. 1 4. 6±3· 1 2.ほ 2. 5 ρ<0. 005
Before use 2 weeks later D / ar r Average soil standard deviation 1 hour later Average Fuji standard deviation Ρ value '
Figure imgf000013_0001
5 Average ± standard deviation pa ed Degree of physical disability 7.1 ± 2. 0 5. 9 ± 3. 0 4. 2 ± 3.3 ρ <0. 01 Mood 8.6 8. 2.2 5. 5 ± 2. 5 5. 3 ± 3. 6 ρ <0. 01 Degree of work and household chores 4.5 5 ± 3. 6 4. 1 ± 3 · 2 3. 3 ± 3.7 7. 4 ± 2. 2 5. 4 ± 2. 4 4. 3 ± 2 · ρ ρ <0. 01 Pain B. 4 ± 0. B 5. 4 ± 2. 1 4. 6 ± 1. 9 ρ <0. 005 Fatigue 9. 0 ± 0. 8 6. 1 ± 2. 6 5. 3 ± 3.3 ρ <0. 01 Mood when waking up 8. 0 ± 2. 2 4. 7 ± 2. 7 3. 7 ± 2. 6 ρ 0. 05 Stiffness 8. 3 ± 1 0 4. 9 ± 2. 3 4. 3 ± 3.1 1 ρ <0. 05 Anxiety 8. 0 ± 2 0 5. 1 ± 2. 9 3. 4 ± 2 3 ρ <0. 005 Degree of depression 7.4 ± 2. 1 4. 6 ± 3 1 2 H 2.5 ρ <0. 005
F IQ合計得点 76. 7±9. 2 51. 8±13. 7 41. 2±1 Β. 4 ρ<0. 005 F IQ total score 76. 7 ± 9. 2 51. 8 ± 13. 7 41. 2 ± 1 Β. 4 ρ <0. 005
[0031] (4)特別調査結果:炭素繊維シート使用中止により症状は再燃した。 [0031] (4) Special survey results: Symptoms recurred after discontinuation of carbon fiber sheet use.
炭素繊維シート二日間継続使用後に炭素繊維シート使用を二週間中断した特別調 查において、使用二日目には疲労感 ·気分'こわばりの FIQ観察項目で改善が得ら れたものの、炭素繊維シート使用中断により痛み ·疲労感 ·気分'こわばりのすべてが 増悪し、炭素繊維シート使用前のレベルに戻ってしまった(図 13参照)。  In the special study where the use of the carbon fiber sheet was interrupted for two weeks after the continuous use of the carbon fiber sheet for two days, the carbon fiber sheet was improved on the second day of use, although improvement was observed in the FIQ observation item of feeling of feeling and stiffness. Discontinuation of use caused all pain, fatigue, and mood stiffness, and returned to the level before using the carbon fiber sheet (see Fig. 13).
[0032] [考察]  [0032] [Discussion]
現時点で FMに対しての特効的治療法は無ぐ薬物療法に加えて、食事療法、運動 療法などのあらゆる補完療法が工夫され提供されて!、る。今回の試験では従来の治 療方法では明らかな改善効果が認められず、難治化している重症型 FM (平均 FIQ指 数 73.2)症例を対象に植物性炭素繊維の治療効果を検討した。 FMでは高頻度に睡 眠障害を伴うことから、この是正を目的として炭素繊維シートをシーツとして就寝時に 用いることを当初の目的としていたが、今回の試験により炭素繊維シートには FMその ものへの治療効果を有することが明らかとなった。 FM患者の症状改善における満足 度は FIQ指数の 10%低下程度で得られることが報告されおり、炭素繊維シート使用 一週間後における FIQ指数 27.5%降下と観察対象症例全例に例外なく効果が認め られたことは特筆すべき治療成績と言える。  At present, in addition to pharmacotherapy, which has no effective treatment for FM, all complementary therapies such as diet therapy and exercise therapy have been devised and provided! RU In this study, the therapeutic effects of plant carbon fiber were examined in severe FM patients (average FIQ index: 73.2), which had not been clearly improved by conventional treatment methods. Since FM often accompanies sleep disorders, the original purpose was to use a carbon fiber sheet as a bed sheet for the purpose of correcting this, but this trial has changed the carbon fiber sheet to FM itself. It became clear that it had a therapeutic effect. It has been reported that satisfaction with improving symptoms in FM patients can be obtained with a 10% decrease in FIQ index, and a 27.5% decrease in FIQ index after one week of use of the carbon fiber sheet, and all patients observed have an effect without exception. This is a remarkable treatment outcome.
[0033] また、これまで食事療法、運動療法などの補完療法の効果判定対象となった FM患 者は FIQ指数で平均 40— 50を呈する比較的軽症群であり、明確な治療効果判定が 困難であつたと推定されるが、今回本発明者らがおこなった試験での対象患者は重 症群であり、患者の日常性'社会性が著しく損なわれていた。 FIQの有意な改善にも かかわらず、「休業」の項目で有意な改善が得られて 、な 、のは調査対象が重症群 であったため、すでに失業 ·寝たきり状態であった症例が含まれていたためと推定さ れる。 [0033] FM patients that have been evaluated for the effectiveness of complementary therapies such as diet therapy and exercise therapy It is estimated that the patients in the relatively mild group with an average of 40-50 in the FIQ index and it was difficult to clearly determine the treatment effect, but the target patients in the study conducted by the present inventors were the severe group The patient's daily life 'sociality was significantly impaired. Despite significant improvement in FIQ, a significant improvement was obtained in the item of “Non-working”, because the subject of the survey was a severe group, and included cases that were already unemployed or bedridden. It is estimated that
[0034] その一方で、炭素繊維シートによる治療効果は FIQ指数で評価される改善のみなら ず、著効例では臥床生活力もの脱却、職場復帰などが可能となるなど、患者個人の 社会的生産性の向上に資する効果も認められて ヽた。疼痛'疲労感 '気分'こわばり 感などの症状に対しては、炭素繊維シートは使用後一時間と短時間で最大に近い効 果をもたらす即効性が観察されている一方で、炭素繊維シートの使用中止により容 易に治療効果がキャンセルされてしまう現象も観察されて 、る。  [0034] On the other hand, the therapeutic effects of carbon fiber sheets are not only improved as assessed by the FIQ index, but in the effective cases, it is possible to get out of bedside vitality, return to work, etc. The effect that contributes to the improvement of sex was also recognized. For symptom such as pain 'fatigue sensation' feeling 'stiffness, the carbon fiber sheet has been observed to have a maximum effect in one hour and a short time after use. It has also been observed that the treatment effect can be easily canceled by discontinuing use.
[0035] また、炭素繊維シート長期使用例の一部で増悪の FIQ項目が観察された理由つい て、観察期間中に大きな気温の低下があったこと、生理があったこと等をあげる症例 が多ぐ炭素繊維シートによる治療効果は根治的治療効果ではないと推定される。治 療効果持続のためには少なくとも炭素繊維シートによる継続治療が必須と考えられる 。また、炭素繊維使用ディバイスとして、シーツ形状ではなく着衣形状なども考慮し、 炭素繊維使用ディバイスの長時間装着も今後検討すべき課題と考えられた。  [0035] In addition, there were cases where the exacerbation of FIQ items was observed in some of the long-term use cases of carbon fiber sheets, such as the fact that there was a significant decrease in temperature during the observation period and the presence of menstruation. It is presumed that the therapeutic effect of many carbon fiber sheets is not a radical therapeutic effect. In order to maintain the therapeutic effect, at least continuous treatment with carbon fiber sheets is considered essential. Considering not only the sheet shape but also the clothing shape as the carbon fiber device, long-term wearing of the carbon fiber device was considered an issue to be examined in the future.
[0036] 炭素繊維の作用メカニズムについては、現時点では不明である。炭素繊維は、遠 赤外線放射効果を有することはすでに実証されて 、る。そのため保温による血流増 加等の身体作用を想定することはできるが、繊維に加わる熱は体温のみであり、炭素 繊維力 放射される遠赤外線は無視できるくらい低レベルであると考えられる。したが つて炭素繊維による FMへの効果は、遠赤外線効果が根本作用ではないと推定され る。  [0036] The mechanism of action of the carbon fiber is unknown at this time. Carbon fiber has already been demonstrated to have a far-infrared radiation effect. For this reason, it is possible to assume bodily effects such as increased blood flow due to heat retention, but the heat applied to the fiber is only the body temperature, and the far infrared rays emitted by the carbon fiber force are considered to be at a negligible level. Therefore, the effect of carbon fiber on FM is presumed that the far-infrared effect is not a fundamental effect.
[0037] 本発明者らの観察では炭素繊維シートにより一部の症例において耳朶血流速度の 著明な増加が認められている (未発表成績)。耳朶血は頸動脈血を反映するとされて いることから、炭素繊維シートにより脳内血流速度が増加することが推定される。炭素 繊維シートの FMSへの臨床効果は中枢神経系作用を介する可能性が推定されるが 、この可能性は、炭素繊維シート長期使用(二週間)で得られた臨床効果で大きな有 意差をもって改善効果が得られた項目が「不安感」、「落ち込み」などの精神症状で あったことからも支持される。すなわち、脳で分泌され、血流に放出された物質は、速 められた血流に乗って、効率良く末梢に供給されることになる。 FMの症状緩和に関 連する物質が脳循環力 末梢に供給されることで FMの症状緩和につながる可能性 が考えられる力 この点については今後の研究課題である。 [0037] According to the observations of the present inventors, a marked increase in earlobe blood flow velocity was observed in some cases with carbon fiber sheets (unpublished results). Since ear phlebotomy is thought to reflect carotid arterial blood, it is presumed that the carbon fiber sheet increases the blood flow velocity in the brain. It is estimated that the clinical effects of carbon fiber sheets on FMS may be via central nervous system action. This possibility was caused by mental symptoms such as “anxiety” and “depression”, which resulted in significant significant improvement in clinical effects obtained by long-term use of carbon fiber sheets (two weeks). It is supported from that. In other words, substances secreted by the brain and released into the bloodstream are efficiently supplied to the periphery along the accelerated bloodstream. The ability of substances related to FM symptomatic relief to lead to cerebral circulatory force being delivered to the periphery, which may lead to FM symptom relief. This is a topic for future research.
[0038] 炭素繊維は難知性 FMに対して、短期間に治療効果を発揮することができるが、根 治的治療効果とは言 ヽ難 、ため、 FM治療のためには炭素繊維を用いた継続治療が 必要である。 FM治療の基礎的治療方法として炭素繊維使用を取り入れた上で、薬 物療法'食事療法 ·運動療法などを展開することにより、これまでより効果的な FM治 療が可能になるものと推定される。 [0038] Carbon fiber can exert a therapeutic effect for FM in the short term, but it is difficult to say that it is a radical therapeutic effect. Therefore, carbon fiber was used for FM treatment. Continuous treatment is necessary. It is estimated that more effective FM treatment will be possible by adopting the use of carbon fiber as the basic treatment method for FM treatment and then developing drug therapy 'diet therapy / exercise therapy'. The
図面の簡単な説明  Brief Description of Drawings
[0039] [図 1]圧痛点の位置を示す説明図である。 FIG. 1 is an explanatory diagram showing the position of a tender point.
[図 2]本発明で使用可能な炭素繊維について、赤外線放射計により放射率を測定し た結果を示すグラフである。  FIG. 2 is a graph showing the results of measuring emissivity with an infrared radiometer for carbon fibers usable in the present invention.
[図 3]本発明で使用可能な炭素繊維について、赤外線放射計により放射率を測定し た結果を示すグラフである。  FIG. 3 is a graph showing the results of measuring emissivity with an infrared radiometer for carbon fibers usable in the present invention.
圆 4]本発明で使用可能な炭素繊維について、赤外線放射計により放射率を測定し た結果を示すグラフである。  圆 4] A graph showing the results of measuring the emissivity of the carbon fiber usable in the present invention with an infrared radiometer.
[図 5]本発明の実施の形態のマットを示す正面図である。  FIG. 5 is a front view showing a mat according to an embodiment of the present invention.
[図 6]本発明の実施の形態のベストを示す (A)正面図、(B)背面図である。  FIG. 6 is a (A) front view and (B) rear view showing a vest according to an embodiment of the present invention.
[図 7]線維筋痛症に関する効果のアンケート項目を示す説明図である。  FIG. 7 is an explanatory diagram showing questionnaire items regarding effects on fibromyalgia.
[図 8]本発明の炭素繊維により使用後 1時間で得られる臨床効果を示すグラフである  FIG. 8 is a graph showing clinical effects obtained in 1 hour after use with the carbon fiber of the present invention.
[図 9]本発明の炭素繊維により 1週間使用で得られる臨床効果を示すグラフである。 FIG. 9 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for one week.
[図 10]本発明の炭素繊維により 1週間使用で得られる臨床効果を示すグラフである。  FIG. 10 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for one week.
[図 11]本発明の炭素繊維により 2週間使用で得られる臨床効果を示すグラフである。  FIG. 11 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for 2 weeks.
[図 12]本発明の炭素繊維により 2週間使用で得られる臨床効果を示すグラフである。 圆 13]本発明の炭素繊維の使用中止の結果を示すグラフである。 符号の説明 FIG. 12 is a graph showing the clinical effect obtained by using the carbon fiber of the present invention for 2 weeks. 13] A graph showing the result of discontinuation of use of the carbon fiber of the present invention. Explanation of symbols
1 マツ卜本体  1 Pine bowl body
2 カバー  2 Cover
3 炭素繊維シート  3 Carbon fiber sheet
4 ンッノ 1 ~~ 4 Nuccino 1 ~~
5 ベスト本体  5 Best body
6 炭素繊維シート  6 Carbon fiber sheet

Claims

請求の範囲 The scope of the claims
[1] 綿花を原料とする炭素繊維から成ることを特徴とする線維筋痛症の症状緩和用繊 維。  [1] A fiber for alleviating symptoms of fibromyalgia characterized by comprising carbon fiber made from cotton.
[2] 木酢液、竹酢液またはその両方を主成分とする処理液を、綿花を原料とする炭素 繊維に含浸 ·乾燥させて成ることを特徴とする線維筋痛症の症状緩和用繊維。  [2] A fiber for alleviating symptoms of fibromyalgia characterized by impregnating and drying carbon fiber made from cotton with a treatment liquid mainly composed of wood vinegar, bamboo vinegar or both.
[3] 前記炭素繊維は、綿花を酸化雰囲気中で加熱して不融化処理または耐炎化処理 を施し、さらに不活性ガス中で加熱し炭素化して成ることを特徴とする請求項 1または[3] The carbon fiber according to claim 1 or 2, wherein the carbon fiber is heated in an oxidizing atmosphere to be infusibilized or flameproofed, and further heated in an inert gas to be carbonized.
2記載の線維筋痛症の症状緩和用繊維。 2. The fiber for symptom alleviation of fibromyalgia according to 2.
[4] 請求項 1, 2または 3記載の線維筋痛症の症状緩和用繊維を含むことを特徴とする 繊維製品。 [4] A fiber product comprising the fibromyalgia symptom-relieving fiber according to claim 1, 2 or 3.
[5] 請求項 1, 2または 3記載の線維筋痛症の症状緩和用繊維を成人の後頭部から臀 部までを覆う範囲に配置して成ることを特徴とするマット。  [5] A mat comprising the fibromyalgia symptom-relieving fiber according to claim 1, 2 or 3 in a range covering from the back of the adult to the buttocks.
[6] 請求項 1, 2または 3記載の線維筋痛症の症状緩和用繊維を、着用したとき、後頭 部、下部頸椎、僧帽筋、棘上筋、第二肋筋、外側上顆、臀部、大転子および膝を覆う 範囲に配置して成ることを特徴とする衣類。 [6] When the fibromyalgia symptom alleviating fiber according to claim 1, 2 or 3 is worn, the occipital region, lower cervical spine, trapezius, supraspinatus, second gluteal muscle, lateral epicondyle, A garment characterized by being arranged in a range that covers the buttocks, greater trochanter and knees.
[7] 請求項 1, 2または 3記載の線維筋痛症の症状緩和用繊維を、着用したとき、後頭 部、下部頸椎、僧帽筋、棘上筋および第二肋筋を覆う範囲に配置して成ることを特 徴とするベスト。 [7] The fibromyalgia symptom alleviating fiber according to claim 1, 2 or 3 is disposed in a range covering the occipital region, the lower cervical spine, the trapezius, the supraspinatus, and the second gluteal muscle when worn. The best that is characterized by.
PCT/JP2006/308392 2006-04-21 2006-04-21 Fiber and fiber products for relieving symptoms of fibromuscular pain WO2007122721A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006525407A JPWO2007122721A1 (en) 2006-04-21 2006-04-21 Fibromyalgia Symptom Relieving Fiber and Textile Products
PCT/JP2006/308392 WO2007122721A1 (en) 2006-04-21 2006-04-21 Fiber and fiber products for relieving symptoms of fibromuscular pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2006/308392 WO2007122721A1 (en) 2006-04-21 2006-04-21 Fiber and fiber products for relieving symptoms of fibromuscular pain

Publications (1)

Publication Number Publication Date
WO2007122721A1 true WO2007122721A1 (en) 2007-11-01

Family

ID=38624649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/308392 WO2007122721A1 (en) 2006-04-21 2006-04-21 Fiber and fiber products for relieving symptoms of fibromuscular pain

Country Status (2)

Country Link
JP (1) JPWO2007122721A1 (en)
WO (1) WO2007122721A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106724350A (en) * 2017-01-18 2017-05-31 李力 A kind of dual temperature control mattress

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11206539A (en) * 1998-01-27 1999-08-03 E Tec:Kk Far infrared sheet using carbon fiber
JP2000160476A (en) * 1998-11-30 2000-06-13 E Tec:Kk Production of carbon fiber and carbon fiber produced thereby
JP2001516404A (en) * 1997-03-14 2001-09-25 メシェ−ブガッティ Method for producing active fabric made of carbon fiber
JP2001342688A (en) * 2000-06-01 2001-12-14 Nisseki House Industry Co Ltd Carbonized raw material for building material and the like, and method of manufacturing the same
JP2003247163A (en) * 2002-02-20 2003-09-05 Yutaka Kawasaki Electromagnetic wave absorber and method for producing the same
JP2004024481A (en) * 2002-06-25 2004-01-29 Yoichi Kadokami Antibacterial medical material

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516404A (en) * 1997-03-14 2001-09-25 メシェ−ブガッティ Method for producing active fabric made of carbon fiber
JPH11206539A (en) * 1998-01-27 1999-08-03 E Tec:Kk Far infrared sheet using carbon fiber
JP2000160476A (en) * 1998-11-30 2000-06-13 E Tec:Kk Production of carbon fiber and carbon fiber produced thereby
JP2001342688A (en) * 2000-06-01 2001-12-14 Nisseki House Industry Co Ltd Carbonized raw material for building material and the like, and method of manufacturing the same
JP2003247163A (en) * 2002-02-20 2003-09-05 Yutaka Kawasaki Electromagnetic wave absorber and method for producing the same
JP2004024481A (en) * 2002-06-25 2004-01-29 Yoichi Kadokami Antibacterial medical material

Also Published As

Publication number Publication date
JPWO2007122721A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
Sau-Fun et al. Development of medical garments and apparel for the elderly and the disabled
Curteza et al. Designing functional clothes for persons with locomotor disabilities
US20100050316A1 (en) Synthetic woven patient gown for preventing and reducing skin wounds
US20090312684A1 (en) Underpad for preventing and reducing skin wounds
US20090308404A1 (en) Fabrics for preventing and reducing skin wounds
Yu Achieving comfort in intimate apparel
JP5642173B2 (en) Improved fabric for preventing and reducing skin wounds
WO2007122721A1 (en) Fiber and fiber products for relieving symptoms of fibromuscular pain
JP2009127157A (en) Therapeutic and/or preventive material for chronic headache, and application of the same
CN202407086U (en) Energy thermal moxibustion shirt
US20130172968A1 (en) Therapuedic undergarments/garments for treatment of Fibromyalgia (FM)
CN210076654U (en) Sore shorts is pressed in prevention
CN102121170B (en) Preparation of effect component fibers of edgoworthia chriysantha lind and application thereof
CN201379903Y (en) Product with far-infrared and magnetic health-care function and health-care underwear
Jung et al. Actual conditions of functional clothing development for the elderly-Based on patent analysis of functional products
Rudolf et al. Protective Garments for Wheelchair Users
CN201557576U (en) Health care waist guard
Skodova et al. Performance of textile materials for the needs of children with skin problems
JPWO2008044785A1 (en) Materials for improving cerebral blood flow and uses thereof
CN210203428U (en) Multi-functional chinese mugwort health preserving wadded jacket
Choi et al. The relationship between practice in lymphedema self-care management and health-related quality of life in breast cancer patients with mastectomy
Glovinsky et al. Sleepwear with lateralized thermal properties for the treatment of sleep disturbance in women
CN211356613U (en) Lower limb warming device for improving blood circulation
CN211672597U (en) Bed nursing clothes
CN206518154U (en) A kind of clothes of waist support and absorbing sweat

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2006525407

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06732200

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06732200

Country of ref document: EP

Kind code of ref document: A1